Immunohistochemical Evaluation of Hormone Receptors in Breast Cancer
- 1 March 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 12 (1) , 8-13
- https://doi.org/10.1097/00129039-200403000-00002
Abstract
To evaluate hormone receptors immunohistochemically, standardized staining procedures and scoring systems are required. The authors previously reported that highly sensitive procedures affected basic factors for technical validation. The aim of the present study was to show the characteristics of scoring systems for highly sensitive procedures. To examine how highly sensitive procedures enhance the staining intensity and increase the positive cell population, two different staining methods were compared. To evaluate scoring systems, three systems--cell counting score, modified immunoreactive score, and H score--were compared using the same samples stained by an autostaining system. It was found that the highly sensitive procedure increased the positive cell population, especially in breast cancers with a low enzyme immunoassay (EIA) level of less than 100 fmol/mg, and strengthened the staining intensity. This enhancement led to a correlation in a logarithmic curve rather than a linear correlation by all three scoring systems. The results showed that scoring systems including a factor of staining intensity did not have an absolute advantage because boosted staining intensity by highly sensitive procedure did not reflect EIA value or protein contents accurately. To the authors' knowledge, there is no report discussing the nonlinear correlation between biochemical and immunohistochemical assay by highly sensitive procedures; however, it is important to select a scoring system and threshold based on nonlinear correlation.Keywords
This publication has 13 references indexed in Scilit:
- Guidelines on endocrine therapy of breast cancerEUSOMAEuropean Journal Of Cancer, 2002
- Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast CancerJournal of Clinical Oncology, 2001
- 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*Journal of Clinical Oncology, 2001
- Immunohistochemical detection of steroid receptors in breast cancer: a working protocolJournal of Clinical Pathology, 2000
- Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group studyInternational Journal of Cancer, 2000
- Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast CancerJournal of Clinical Oncology, 1999
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trialsCancer, 1996
- Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancerPathology - Research and Practice, 1993
- Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06.Journal of Clinical Oncology, 1988